Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10158)
All Articles published online
|
Publishing Process of This Article
|
Feb 7, 2015 (publication date) through May 10, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Bae JM, Lee TH, Cho NY, Kim TY, Kang GH. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients. World J Gastroenterol 2015; 21(5): 1457-1467 [PMID: 25663765 DOI: 10.3748/wjg.v21.i5.1457] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i5/1457.htm |
| Number | Citing Articles |
| 1 |
Eric R. Fearon, Emina H. Huang. CDX2: Linking Cell and Patient Fates in Colon Cancer. Cell Stem Cell 2016; 18(2): 168 doi: 10.1016/j.stem.2016.01.011
|
| 2 |
CDX2 as a Prognostic Biomarker in Colon Cancer. New England Journal of Medicine 2016; 374(22): 2182 doi: 10.1056/NEJMc1602584
|
| 3 |
Jeong Mo Bae, Ye-Young Rhee, Kyung Ju Kim, Xianyu Wen, Young Seok Song, Nam-Yun Cho, Jung Ho Kim, Gyeong Hoon Kang. Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype–high colorectal cancers?. Human Pathology 2016; 47(1): 85 doi: 10.1016/j.humpath.2015.09.008
|
| 4 |
Weimin Xu, Yilian Zhu, Wei Shen, Wenjun Ding, Tingyu Wu, Yuegui Guo, Xiaobing Chen, Mingxia Zhou, Yingwei Chen, Long Cui, Peng Du. Combination of CDX2 expression and T stage improves prognostic prediction of colorectal cancer. Journal of International Medical Research 2019; 47(5): 1829 doi: 10.1177/0300060518819620
|
| 5 |
Jingsheng Yuan, Zhijie Yin, Kaixiong Tao, Guobing Wang, Jinbo Gao. Homeobox protein CDX2 as a prognostic biomarker in solid malignancies: a meta-analysis. Oncotarget 2017; 8(51): 89160 doi: 10.18632/oncotarget.20808
|
| 6 |
Lanisha D Fuller, Andrew Dunn, Aaron R Huber, Monika Vyas, Raul S Gonzalez. Clinicopathologic Features of Gynecologic Malignancies Presenting Clinically as Colonic Malignancies. American Journal of Clinical Pathology 2022; 157(1): 82 doi: 10.1093/ajcp/aqab097
|
| 7 |
Soledad Iseas, Juan M. Sendoya, Juan Robbio, Mariana Coraglio, Mirta Kujaruk, Vanesa Mikolaitis, Mariana Rizzolo, Ana Cabanne, Gonzalo Ruiz, Rubén Salanova, Ubaldo Gualdrini, Guillermo Méndez, Marina Antelo, Marcela Carballido, Cecilia Rotondaro, Julieta Viglino, Martín Eleta, Alejandro Di Sibio, Osvaldo L. Podhajcer, Enrique Roca, Andrea S. Llera, Mariano Golubicki, Martín Carlos Abba. Prognostic Impact of An Integrative Landscape of Clinical, Immune, and Molecular Features in Non-Metastatic Rectal Cancer. Frontiers in Oncology 2022; 11 doi: 10.3389/fonc.2021.801880
|
| 8 |
Kevin Tong, Oscar Pellón-Cárdenas, Veerin R. Sirihorachai, Bailey N. Warder, Om A. Kothari, Ansu O. Perekatt, Emily E. Fokas, Robert L. Fullem, Anbo Zhou, Joshua K. Thackray, Hiep Tran, Lanjing Zhang, Jinchuan Xing, Michael P. Verzi. Degree of Tissue Differentiation Dictates Susceptibility to BRAF-Driven Colorectal Cancer. Cell Reports 2017; 21(13): 3833 doi: 10.1016/j.celrep.2017.11.104
|
| 9 |
Apurva Atak, Samiksha Khurana, Kishore Gollapalli, Panga Jaipal Reddy, Roei Levy, Stav Ben-Salmon, Dror Hollander, Maya Donyo, Anke Heit, Agnes Hotz-Wagenblatt, Hadas Biran, Roded Sharan, Shailendra Rane, Ashutosh Shelar, Gil Ast, Sanjeeva Srivastava. Quantitative mass spectrometry analysis reveals a panel of nine proteins as diagnostic markers for colon adenocarcinomas. Oncotarget 2018; 9(17): 13530 doi: 10.18632/oncotarget.24418
|
| 10 |
Yunshuai Wang, Zhaohui Li, Wenxian Li, Shuaifeng Liu, Baowei Han. Methylation of CDX2 gene promoter in the prediction of treatment efficacy in colorectal cancer. Oncology Letters 2018; doi: 10.3892/ol.2018.8670
|
| 11 |
Aya Nishiuchi, Shigeo Hisamori, Masazumi Sakaguchi, Keita Fukuyama, Nobuaki Hoshino, Yoshiro Itatani, Shusaku Honma, Hisatsugu Maekawa, Tatsuto Nishigori, Shigeru Tsunoda, Kazutaka Obama, Hiroyuki Miyoshi, Yohei Shimono, M. Mark Taketo, Yoshiharu Sakai. MicroRNA-9-5p-CDX2 Axis: A Useful Prognostic Biomarker for Patients with Stage II/III Colorectal Cancer. Cancers 2019; 11(12): 1891 doi: 10.3390/cancers11121891
|
| 12 |
Nevena Ilieva, Desislava Tashkova, Dmitrii Staykov, Denitsa Serteva, Yana Feodorova, Nikolay Mehterov, Angelina Mollova, Svitlana Bachurska. Immunohistochemical expression of CK20, CK7, and CDX2 in colorectal carcinoma in correlation with pathomorphological characteristics. Folia Medica 2022; 64(2): 214 doi: 10.3897/folmed.64.e60950
|
| 13 |
Yasuyuki Shigematsu, Kentaro Inamura, Yoshihiro Mise, Akio Saiura, Emil Rehnberg, Noriko Yamamoto, Yuichi Ishikawa, Shunji Takahashi, Hiroaki Kanda. CDX2 expression is concordant between primary colorectal cancer lesions and corresponding liver metastases independent of chemotherapy: a single-center retrospective study in Japan. Oncotarget 2018; 9(24): 17056 doi: 10.18632/oncotarget.24842
|
| 14 |
Jeong Mo Bae, Jung Ho Kim, Gyeong Hoon Kang. Molecular Subtypes of Colorectal Cancer and Their Clinicopathologic Features, With an Emphasis on the Serrated Neoplasia Pathway. Archives of Pathology & Laboratory Medicine 2016; 140(5): 406 doi: 10.5858/arpa.2015-0310-RA
|
| 15 |
Camille Balbinot, Olivier Armant, Nabila Elarouci, Laetitia Marisa, Elisabeth Martin, Etienne De Clara, Alina Onea, Jacqueline Deschamps, Felix Beck, Jean-Noël Freund, Isabelle Duluc. The Cdx2 homeobox gene suppresses intestinal tumorigenesis through non–cell-autonomous mechanisms. Journal of Experimental Medicine 2018; 215(3): 911 doi: 10.1084/jem.20170934
|
| 16 |
Paige N. Vega, Avlant Nilsson, Manu P. Kumar, Hiroaki Niitsu, Alan J. Simmons, James Ro, Jiawei Wang, Zhengyi Chen, Brian A. Joughin, Wei Li, Eliot T. McKinley, Qi Liu, Joseph T. Roland, M. Kay Washington, Robert J. Coffey, Douglas A. Lauffenburger, Ken S. Lau. Cancer-Associated Fibroblasts and Squamous Epithelial Cells Constitute a Unique Microenvironment in a Mouse Model of Inflammation-Induced Colon Cancer. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.878920
|
| 17 |
Ida V. Lundberg, Sofia Edin, Vincy Eklöf, Åke Öberg, Richard Palmqvist, Maria L. Wikberg. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer. BMC Cancer 2016; 16(1) doi: 10.1186/s12885-016-2509-5
|
| 18 |
Fabiola Pabst BREMER, Nicolau Gregori CZECZKO, Luiz Martins COLLAÇO, Letícia Elizabeth Augustin Czeczko RUTZ, Guilherme GIONEDIS, Camila Kienen YAMAKAWA. ARE CDX2, BETA-CATENIN AND WNT IMMUNOMARCHERS USEFUL FOR EVALUATING THE CHANCE OF DISEASE PROGRESSION OR EVOLUTION TO DEATH IN PATIENTS WITH COLORECTAL CANCER?. ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) 2020; 33(3) doi: 10.1590/0102-672020200003e1534
|
| 19 |
Julien Taieb, Thierry André, Edouard Auclin. Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives. Cancer Treatment Reviews 2019; 75: 1 doi: 10.1016/j.ctrv.2019.02.002
|
| 20 |
Krittiya Korphaisarn, Kanjana Sukhokanjanachusak, Ananya Pongpaibul, Vitoon Chinswangwatanakul, Charuwan Akewanlop. Loss of CDX‐2 expression is an independent poor prognostic biomarker in patients with early‐stage deficient mismatch repair colorectal cancer. Asia-Pacific Journal of Clinical Oncology 2022; 18(3): 249 doi: 10.1111/ajco.13612
|
| 21 |
James Saller, Sameer Al Diffalha, Kevin Neill, Rahill A. Bhaskar, Cecilia Oliveri, David Boulware, Henry Levine, Isaac Kalvaria, F. Scott Corbett, Arun Khazanchi, Jason Klapman, Domenico Coppola. CDX-2 Expression in Esophageal Biopsies Without Goblet Cell Intestinal Metaplasia May Be Predictive of Barrett’s Esophagus. Digestive Diseases and Sciences 2020; 65(7): 1992 doi: 10.1007/s10620-019-05914-x
|
| 22 |
Michela Roberto, Giulia Arrivi, Emanuela Pilozzi, Andrea Montori, Genoveffa Balducci, Paolo Mercantini, Andrea Laghi, Debora Ierinò, Martina Panebianco, Daniele Marinelli, Silverio Tomao, Paolo Marchetti, Federica Mazzuca. The Potential Role of Genomic Signature in Stage II Relapsed Colorectal Cancer (CRC) Patients: A Mono-Institutional Study. Cancer Management and Research 2022; : 1353 doi: 10.2147/CMAR.S342612
|
| 23 |
Nair Lopes, Christian Holst Bergsland, Merete Bjørnslett, Teijo Pellinen, Aud Svindland, Arild Nesbakken, Raquel Almeida, Ragnhild A. Lothe, Leonor David, Jarle Bruun. Digital image analysis of multiplex fluorescence IHC in colorectal cancer recognizes the prognostic value of CDX2 and its negative correlation with SOX2. Laboratory Investigation 2020; 100(1): 120 doi: 10.1038/s41374-019-0336-4
|
| 24 |
Jiezhen Li, Qiang Zeng, Jie Lin, Haijian Huang, Lingfeng Chen. Loss of SATB2 and CDX2 expression is associated with DNA mismatch repair protein deficiency and BRAF mutation in colorectal cancer. Medical Molecular Morphology 2024; 57(1): 1 doi: 10.1007/s00795-023-00366-9
|
| 25 |
Seema Bhatlekar, Jeremy Z. Fields, Bruce M. Boman. Role of HOX Genes in Stem Cell Differentiation and Cancer. Stem Cells International 2018; 2018: 1 doi: 10.1155/2018/3569493
|
| 26 |
Piero Dalerba. Estimating the Economic Value of CDX2 as a Predictive Biomarker to Guide Treatment Decisions in Stage II Colon Cancer. Value in Health 2022; 25(3): 382 doi: 10.1016/j.jval.2021.09.006
|
| 27 |
İlknur ÇALIK, Muhammet ÇALIK, İbrahim Hanifi ÖZERCAN, Adile Ferda DAĞLI, Gökhan ARTAŞ, Gülistan TÜRKEN, Burcu SARIKAYA. Decreased CDX2 Expression Adversely Effect On Prognosis Of Patients With Colorectal Cancer. Dicle Tıp Dergisi 2020; : 57 doi: 10.5798/dicletip.706005
|
| 28 |
Changqing Ma, Dane Olevian, Caitlyn Miller, Cameron Herbst, Priya Jayachandran, Margaret M. Kozak, Daniel T. Chang, Reetesh K. Pai. SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer. Modern Pathology 2019; 32(8): 1217 doi: 10.1038/s41379-019-0265-1
|
| 29 |
Seung-Yeon Yoo, Ji-Ae Lee, Yunjoo Shin, Nam-Yun Cho, Jeong Mo Bae, Gyeong Hoon Kang. Clinicopathological Characterization and Prognostic Implication of SMAD4 Expression in Colorectal Carcinoma. Journal of Pathology and Translational Medicine 2019; 53(5): 289 doi: 10.4132/jptm.2019.06.07
|
| 30 |
Cristian Perna, Antonia Navarro, Ignacio Ruz-Caracuel, Tamara Caniego-Casas, Eva Cristóbal, Susanna Leskelä, Federico Longo, Alejandra Caminoa, Almudena Santón, Reyes Ferreiro, David Pizarro, María Luisa Palacios-Berraquero, José Palacios. Molecular Heterogeneity of High Grade Colorectal Adenocarcinoma. Cancers 2021; 13(2): 233 doi: 10.3390/cancers13020233
|
| 31 |
Evi Abada, Ifeoma C. Anaya, Othuke Abada, Anthony Lebbos, Rafic Beydoun. Colorectal adenocarcinoma with enteroblastic differentiation: diagnostic challenges of a rare case encountered in clinical practice. Journal of Pathology and Translational Medicine 2022; 56(2): 97 doi: 10.4132/jptm.2021.10.28
|
| 32 |
C. Pilati, J. Taieb, R. Balogoun, L. Marisa, A. de Reyniès, P. Laurent-Puig. CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification. Annals of Oncology 2017; 28(5): 1032 doi: 10.1093/annonc/mdx066
|
| 33 |
Jeong Mo Bae, Jung Ho Kim, Hyeon Jeong Oh, Hye Eun Park, Tae Hun Lee, Nam-Yun Cho, Gyeong Hoon Kang. Downregulation of acetyl-CoA synthetase 2 is a metabolic hallmark of tumor progression and aggressiveness in colorectal carcinoma. Modern Pathology 2017; 30(2): 267 doi: 10.1038/modpathol.2016.172
|
| 34 |
Philip D. Dunne, Helen G. Coleman, Peter Bankhead, Matthew Alderdice, Ronan T. Gray, Stephen McQuaid, Victoria Bingham, Maurice B. Loughrey, Jacqueline A. James, Amy M.B. McCorry, Alan Gilmore, Caitriona Holohan, Dirk Klingbiel, Sabine Tejpar, Patrick G. Johnston, Darragh G. McArt, Federica Di Nicolantonio, Daniel B. Longley, Mark Lawler. Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer. Oncotarget 2018; 9(17): 13834 doi: 10.18632/oncotarget.24481
|
| 35 |
Sabine Jägle, Hauke Busch, Vivien Freihen, Sven Beyes, Monika Schrempp, Melanie Boerries, Andreas Hecht, Robert A. Weinberg. SNAIL1-mediated downregulation of FOXA proteins facilitates the inactivation of transcriptional enhancer elements at key epithelial genes in colorectal cancer cells. PLOS Genetics 2017; 13(11): e1007109 doi: 10.1371/journal.pgen.1007109
|
| 36 |
Kjersti Elvestad Hestetun, Kristine Aasebø, Nina Benedikte Rosenlund, Yvonne Müller, Olav Dahl, Mette Pernille Myklebust. Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II–III colon cancer. Modern Pathology 2021; 34(1): 161 doi: 10.1038/s41379-020-0634-9
|
| 37 |
Mitsukuni Suenaga, Marta Schirripa, Shu Cao, Wu Zhang, Chiara Cremolini, Sara Lonardi, Satoshi Okazaki, Martin D. Berger, Yuji Miyamoto, Shivani Soni, Afsaneh Barzi, Toshiharu Yamaguchi, Fotios Loupakis, Alfredo Falcone, Heinz-Josef Lenz. Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. The Pharmacogenomics Journal 2021; 21(3): 285 doi: 10.1038/s41397-021-00207-x
|
| 38 |
Lijing Yang, Lei Tu, Shilpa Bisht, Yiqing Mao, Daniel Petkovich, Sara-Jayne Thursby, Jinxiao Liang, Nibedita Patel, Ray-Whay Chiu Yen, Tina Largent, Cynthia Zahnow, Malcolm Brock, Kathy Gabrielson, Kevan J. Salimian, Stephen B. Baylin, Hariharan Easwaran. Tissue-location-specific transcription programs drive tumor dependencies in colon cancer. Nature Communications 2024; 15(1) doi: 10.1038/s41467-024-45605-4
|
| 39 |
Ben Y. Zhang, Jeremy C. Jones, Andrew M. Briggler, Joleen M. Hubbard, Benjamin R. Kipp, Daniel J. Sargent, Jesse G. Dixon, Axel Grothey. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer. Clinical Colorectal Cancer 2017; 16(2): 124 doi: 10.1016/j.clcc.2016.09.003
|
| 40 |
Mary Familari, Phil Chi Khang Au, Robb U. de Iongh, Yolanda Cruz, Lynne Selwood. Expression analysis of Cdx2 and Pou5f1 in a marsupial, the stripe‐faced dunnart, during early development. Molecular Reproduction and Development 2016; 83(2): 108 doi: 10.1002/mrd.22597
|
| 41 |
Ji-Ae Lee, Hye Eun Park, Hye-Yeong Jin, Lingyan Jin, Nam-Yun Cho, Jeong Mo Bae, Jung Ho Kim, Gyeong Hoon Kang. Concomitant expression patterns of CDX2 and SATB2 as prognostic factors in stage III colorectal cancers. Annals of Diagnostic Pathology 2024; 71: 152289 doi: 10.1016/j.anndiagpath.2024.152289
|
| 42 |
Camille Balbinot, Marie Vanier, Olivier Armant, Asmaa Nair, Julien Penichon, Christine Soret, Elisabeth Martin, Thoueiba Saandi, Jean-Marie Reimund, Jacqueline Deschamps, Felix Beck, Claire Domon-Dell, Isabelle Gross, Isabelle Duluc, Jean-Noël Freund. Fine-tuning and autoregulation of the intestinal determinant and tumor suppressor homeobox gene CDX2 by alternative splicing. Cell Death & Differentiation 2017; 24(12): 2173 doi: 10.1038/cdd.2017.140
|
| 43 |
Ugo Testa, Elvira Pelosi, Germana Castelli. Colorectal Cancer: Genetic Abnormalities, Tumor Progression, Tumor Heterogeneity, Clonal Evolution and Tumor-Initiating Cells. Medical Sciences 2018; 6(2): 31 doi: 10.3390/medsci6020031
|
| 44 |
Mounatadher Al-Duhaidahawi. Role of CDX2 Marker in Patients with Colorectal Cancer. Biomedicine and Chemical Sciences 2023; 2(1): 11 doi: 10.48112/bcs.v2i1.321
|
| 45 |
Ivan Vlahović, Jasmina Rajc, Ivan Švagelj, Krešimir Šolić, Dražen Švagelj. Potential predictors for CDX2 expression loss and mismatch repair deficiency in colorectal cancer. Pathology and Oncology Research 2023; 29 doi: 10.3389/pore.2023.1610908
|
| 46 |
Massimiliano Berretta, Lara Alessandrini, Chiara De Divitiis, Guglielmo Nasti, Arben Lleshi, Raffaele Di Francia, Gaetano Facchini, Carla Cavaliere, Carlo Buonerba, Vincenzo Canzonieri. Serum and tissue markers in colorectal cancer: State of art. Critical Reviews in Oncology/Hematology 2017; 111: 103 doi: 10.1016/j.critrevonc.2017.01.007
|
| 47 |
Janina Graule, Kristin Uth, Elia Fischer, Irene Centeno, José A. Galván, Micha Eichmann, Tilman T. Rau, Rupert Langer, Heather Dawson, Ulrich Nitsche, Peter Traeger, Martin D. Berger, Beat Schnüriger, Marion Hädrich, Peter Studer, Daniel Inderbitzin, Alessandro Lugli, Mario P. Tschan, Inti Zlobec. CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway. Clinical Epigenetics 2018; 10(1) doi: 10.1186/s13148-018-0548-2
|
| 48 |
Lili Duan, Wanli Yang, Xiaoqian Wang, Wei Zhou, Yujie Zhang, Jinqiang Liu, Hongwei Zhang, Qingchuan Zhao, Liu Hong, Daiming Fan. Advances in prognostic markers for colorectal cancer. Expert Review of Molecular Diagnostics 2019; 19(4): 313 doi: 10.1080/14737159.2019.1592679
|
| 49 |
Jeong Mo Bae, Jung Ho Kim, Yoonjin Kwak, Dae-Won Lee, Yongjun Cha, Xianyu Wen, Tae Hun Lee, Nam-Yun Cho, Seung-Yong Jeong, Kyu Joo Park, Sae Won Han, Hye Seung Lee, Tae-You Kim, Gyeong Hoon Kang. Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system. British Journal of Cancer 2017; 116(8): 1012 doi: 10.1038/bjc.2017.52
|
| 50 |
Yasuyuki Shigematsu, Kentaro Inamura, Noriko Yamamoto, Yoshihiro Mise, Akio Saiura, Yuichi Ishikawa, Shunji Takahashi, Hiroaki Kanda. Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis. BMC Cancer 2018; 18(1) doi: 10.1186/s12885-018-4902-8
|
| 51 |
Jordi Badia-Ramentol, Francisco Gimeno-Valiente, Elena Duréndez, Carolina Martínez-Ciarpaglini, Jenniffer Linares, Mar Iglesias, Andrés Cervantes, Alexandre Calon, Noelia Tarazona. The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice. Cancer Treatment Reviews 2023; 121: 102643 doi: 10.1016/j.ctrv.2023.102643
|
| 52 |
Mitsukuni Suenaga, Shu Cao, Wu Zhang, Satoshi Matsusaka, Satoshi Okazaki, Martin D. Berger, Yuji Miyamoto, Marta Schirripa, Afsaneh Barzi, Noriko Yamamoto, Toshiharu Yamaguchi, Heinz-Josef Lenz. Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer. Pharmacogenetics and Genomics 2021; 31(1): 10 doi: 10.1097/FPC.0000000000000416
|
| 53 |
Tessa P. Sandberg, Iris Sweere, Gabi W. van Pelt, Hein Putter, Louis Vermeulen, Peter J. Kuppen, Rob A. E. M. Tollenaar, Wilma E. Mesker. Prognostic value of low CDX2 expression in colorectal cancers with a high stromal content – a short report. Cellular Oncology 2019; 42(3): 397 doi: 10.1007/s13402-019-00436-0
|
| 54 |
J. Olsen, S. Eiholm, L.T. Kirkeby, M.L.M. Espersen, P. Jess, I. Gögenür, J. Olsen, J.T. Troelsen. CDX2 downregulation is associated with poor differentiation and MMR deficiency in colon cancer. Experimental and Molecular Pathology 2016; 100(1): 59 doi: 10.1016/j.yexmp.2015.11.009
|
| 55 |
Kristine Aasebø, Anca Dragomir, Magnus Sundström, Artur Mezheyeuski, Per-Henrik Edqvist, Geir Egil Eide, Fredrik Ponten, Per Pfeiffer, Bengt Glimelius, Halfdan Sorbye. CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.00008
|
| 56 |
Desislava Tashkova, Nevena Ilieva, Denitsa Serteva, Yana Feodorova, Nikolay Mehterov, Angelina Mollova, Svitlana Bachurska. Immunohistochemical phenotype of colorectal carcinoma in patients with KRAS mutation and mismatch repair status. Folia Medica 2023; 65(3): 378 doi: 10.3897/folmed.65.e81334
|
| 57 |
Adel Shahnam, Elizabeth Paver, Bella Nguyen, Mitali Fadia, Sayed Ali. Prognostic Utility of CDX2 and PD-L1 in Rectal Cancer. Applied Immunohistochemistry & Molecular Morphology 2020; 28(6): e53 doi: 10.1097/PAI.0000000000000752
|
| 58 |
Takashi Murakami, Takashi Yao, Noboru Yatagai, Yuya Yamashiro, Tsuyoshi Saito, Naoto Sakamoto, Akihito Nagahara. Colorectal adenocarcinoma with enteroblastic differentiation: a clinicopathological study of five cases. Histopathology 2020; 76(2): 325 doi: 10.1111/his.13973
|
| 59 |
Sara Ribeirinho-Soares, Diana Pádua, Ana Luísa Amaral, Elvia Valentini, Daniela Azevedo, Cristiana Marques, Rita Barros, Filipa Macedo, Patrícia Mesquita, Raquel Almeida. Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients. BMC Cancer 2021; 21(1) doi: 10.1186/s12885-021-08070-6
|
| 60 |
Torben Frøstrup Hansen, Sanne Kjær-Frifeldt, Ann Christina Eriksen, Jan Lindebjerg, Lars Henrik Jensen, Flemming Brandt Sørensen, Anders Jakobsen. Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts. British Journal of Cancer 2018; 119(11): 1367 doi: 10.1038/s41416-018-0285-5
|
| 61 |
Laura M Warmke, Nolan Maloney, Cheuk Hong Leung, Heather Lin, Alexander J Lazar, Wei-Lien Wang. SATB2 Expression in Undifferentiated Pleomorphic Sarcomas of Bone. American Journal of Clinical Pathology 2022; 158(2): 235 doi: 10.1093/ajcp/aqac033
|
| 62 |
Shafigheh Asgari-Karchekani, Mohammad Karimian, Tahereh Mazoochi, Maryam Akhavan Taheri, Tahereh Khamehchian. CDX2 Protein Expression in Colorectal Cancer and ItsCorrelation with Clinical and Pathological Characteristics, Prognosis, and Survival Rate of Patients. Journal of Gastrointestinal Cancer 2020; 51(3): 844 doi: 10.1007/s12029-019-00314-w
|
| 63 |
E. Auclin, A. Zaanan, D. Vernerey, R. Douard, C. Gallois, P. Laurent-Puig, F. Bonnetain, J. Taieb. Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. Annals of Oncology 2017; 28(5): 958 doi: 10.1093/annonc/mdx030
|
| 64 |
Gianluca Tomasello, Sandro Barni, Luca Turati, Michele Ghidini, Ezio Pezzica, Rodolfo Passalacqua, Fausto Petrelli. Association of CDX2 Expression With Survival in Early Colorectal Cancer: A Systematic Review and Meta-analysis. Clinical Colorectal Cancer 2018; 17(2): 97 doi: 10.1016/j.clcc.2018.02.001
|
| 65 |
Matthew J. Cecchini, Joanna C. Walsh, Jeremy Parfitt, Subrata Chakrabarti, Rohann J. Correa, Mary J. MacKenzie, David K. Driman. CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer. Human Pathology 2019; 90: 70 doi: 10.1016/j.humpath.2019.05.005
|
| 66 |
Jarle Bruun, Anita Sveen, Rita Barros, Peter W. Eide, Ina Eilertsen, Matthias Kolberg, Teijo Pellinen, Leonor David, Aud Svindland, Olli Kallioniemi, Marianne G. Guren, Arild Nesbakken, Raquel Almeida, Ragnhild A. Lothe. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer. Molecular Oncology 2018; 12(9): 1639 doi: 10.1002/1878-0261.12347
|
| 67 |
Naoya Sakamoto, Ying Feng, Carmine Stolfi, Yuki Kurosu, Maranne Green, Jeffry Lin, Megan E Green, Kazuhiro Sentani, Wataru Yasui, Martin McMahon, Karin M Hardiman, Jason R Spence, Nobukatsu Horita, Joel K Greenson, Rork Kuick, Kathleen R Cho, Eric R Fearon. BRAFV600E cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis. eLife 2017; 6 doi: 10.7554/eLife.20331
|
| 68 |
Brett S. Walker, Luai R. Zarour, Nicole Wieghard, Alexandra C. Gallagher, John R. Swain, Sheila Weinmann, Christian Lanciault, Kevin Billingsley, V. Liana Tsikitis, Melissa H. Wong. Stem Cell Marker Expression in Early Stage Colorectal Cancer is Associated with Recurrent Intestinal Neoplasia. World Journal of Surgery 2020; 44(10): 3501 doi: 10.1007/s00268-020-05586-z
|
| 69 |
Nadine Platet, Isabelle Hinkel, Ludovic Richert, Devadarssen Murdamoothoo, Ahlam Moufok-Sadoun, Marie Vanier, Philippe Lavalle, Christian Gaiddon, Dominique Vautier, Jean-Noel Freund, Isabelle Gross. The tumor suppressor CDX2 opposes pro-metastatic biomechanical modifications of colon cancer cells through organization of the actin cytoskeleton. Cancer Letters 2017; 386: 57 doi: 10.1016/j.canlet.2016.10.040
|
| 70 |
María Arriba, Juan L. García, Daniel Rueda, Jessica Pérez, Lorena Brandariz, Oana A. Nutu, Laura Alonso, Yolanda Rodríguez, Miguel Urioste, Rogelio González-Sarmiento, José Perea. Unsupervised Analysis of Array Comparative Genomic Hybridization Data from Early-Onset Colorectal Cancer Reveals Equivalence with Molecular Classification and Phenotypes. Neoplasia 2017; 19(1): 28 doi: 10.1016/j.neo.2016.11.006
|
| 71 |
Jeong Mo Bae, Jung Ho Kim, Jeong Hwan Park, Hye Eun Park, Nam‐Yun Cho, Gyeong Hoon Kang. Clinicopathological and molecular implications of aberrant thyroid transcription factor‐1 expression in colorectal carcinomas: an immunohistochemical analysis of 1319 cases using three different antibody clones. Histopathology 2018; 72(3): 423 doi: 10.1111/his.13398
|
| 72 |
Da Huang, Fan Xiao, Haibin Hao, Fuzhou Hua, Zhenzhong Luo, Zhaoxia Huang, Qing Li, Sha Chen, Xiuzhi Cheng, Xinyue Zhang, Weilan Fang, Xiaoyun Hu, Fanrong Liu. JARID1B promotes colorectal cancer proliferation and Wnt/β-catenin signaling via decreasing CDX2 level. Cell Communication and Signaling 2020; 18(1) doi: 10.1186/s12964-020-00660-4
|
| 73 |
Daiki Hirano, Yuji Urabe, Shinji Tanaka, Koki Nakamura, Yuki Ninomiya, Ryo Yuge, Ryohei Hayashi, Shiro Oka, Yasuhiko Kitadai, Fumio Shimamoto, Koji Arihiro, Kazuaki Chayama, Masaru Katoh. Early-stage serrated adenocarcinomas are divided into several molecularly distinct subtypes. PLOS ONE 2019; 14(2): e0211477 doi: 10.1371/journal.pone.0211477
|
| 74 |
Fernando Alarid-Escudero, Deborah Schrag, Karen M. Kuntz. CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis. Value in Health 2022; 25(3): 409 doi: 10.1016/j.jval.2021.07.019
|
| 75 |
Jianbao Zheng, Sai He, Jie Qi, Xiaolong Wang, Junhui Yu, Yunhua Wu, Qi Gao, Kai Wang, Xuejun Sun. Targeted CDX2 expression inhibits aggressive phenotypes of colon cancer cells in vitro and in vivo. International Journal of Oncology 2017; 51(2): 478 doi: 10.3892/ijo.2017.4040
|
| 76 |
Luca Reggiani Bonetti, Simona Lionti, Enrica Vitarelli, Valeria Barresi. Prognostic significance of CDX2 immunoexpression in poorly differentiated clusters of colorectal carcinoma. Virchows Archiv 2017; 471(6): 731 doi: 10.1007/s00428-017-2219-7
|
| 77 |
Ji Ae Lee, Mi-Kyoung Seo, Seung-Yeon Yoo, Nam-Yun Cho, Yoonjin Kwak, Kyoungbun Lee, Jung Ho Kim, Gyeong Hoon Kang. Comprehensive clinicopathologic, molecular, and immunologic characterization of colorectal carcinomas with loss of three intestinal markers, CDX2, SATB2, and KRT20. Virchows Archiv 2022; 480(3): 543 doi: 10.1007/s00428-021-03260-w
|
| 78 |
Zhi Huang, Chuanlin Wang, Qiujin Huang, Zhiqiang Yan, Zhaohui Yin. Hungatella hathewayi impairs the sensitivity of colorectal cancer cells to 5-FU through decreasing CDX2 expression. Human Cell 2023; 36(6): 2055 doi: 10.1007/s13577-023-00938-y
|
| 79 |
Piero Dalerba, Debashis Sahoo, Soonmyung Paik, Xiangqian Guo, Greg Yothers, Nan Song, Nate Wilcox-Fogel, Erna Forgó, Pradeep S. Rajendran, Stephen P. Miranda, Shigeo Hisamori, Jacqueline Hutchison, Tomer Kalisky, Dalong Qian, Norman Wolmark, George A. Fisher, Matt van de Rijn, Michael F. Clarke. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. New England Journal of Medicine 2016; 374(3): 211 doi: 10.1056/NEJMoa1506597
|
| 80 |
Seung-Hee Cho, Byung-Joon Seung, Soo-Hyeon Kim, Min-Kyung Bae, Ha-Young Lim, Jung-Hyang Sur. CDX-2 Protein and mRNA Expression in Canine Intestinal Adenocarcinoma. Journal of Comparative Pathology 2021; 184: 24 doi: 10.1016/j.jcpa.2021.01.010
|
| 81 |
Sonali Pal, Manoj Garg, Amit Kumar Pandey. Colon Cancer Diagnosis and Therapy. 2021; : 123 doi: 10.1007/978-3-030-63369-1_8
|
| 82 |
Jagdeep Singh, N G. Rajesh, Biswajit Dubashi, Nanda K. Maroju, Prasanth Ganesan, Kiran K. Matta, I Charles, Smita Kayal. Pattern of Expression of CDX2 in Colorectal Cancer and its Role in Prognosis: An Ambispective Observational Study. Indian Journal of Medical and Paediatric Oncology 2022; doi: 10.1055/s-0042-1750207
|
| 83 |
Alberto Puccini, Martin D. Berger, Wu Zhang, Heinz-Josef Lenz. What We Know About Stage II and III Colon Cancer: It’s Still Not Enough. Targeted Oncology 2017; 12(3): 265 doi: 10.1007/s11523-017-0494-5
|
| 84 |
Pablo Azcue, David Guerrero Setas, Ignacio Encío, Berta Ibáñez-Beroiz, María Mercado, Ruth Vera, María Luisa Gómez-Dorronsoro. A Novel Prognostic Biomarker Panel for Early-Stage Colon Carcinoma. Cancers 2021; 13(23): 5909 doi: 10.3390/cancers13235909
|
| 85 |
Pina Ziranu, Andrea Pretta, Marta Pozzari, Antonio Maccioni, Manuela Badiali, Daniela Fanni, Eleonora Lai, Clelia Donisi, Mara Persano, Clara Gerosa, Marco Puzzoni, Fabio Bardanzellu, Rossano Ambu, Valeria Pusceddu, Marco Dubois, Giulia Cerrone, Marco Migliari, Sara Murgia, Dario Spanu, Gianluca Pretta, Valentina Aimola, Francesca Balconi, Stefania Murru, Gavino Faa, Mario Scartozzi. CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-31538-3
|